Phenoxybenzamine Shortage: What Providers and Prescribers Need to Know in 2026

Phenoxybenzamine (Dibenzyline) presents a well-recognized access challenge for the endocrinologists, urologists, and endocrine surgeons who prescribe it. As of 2026, the situation remains largely unchanged: phenoxybenzamine is not widely stocked at retail pharmacies, costs significantly more than its alternatives, and patients routinely call their care team in distress after failing to fill the prescription.

This guide is designed to help prescribers proactively manage access barriers and make informed decisions when phenoxybenzamine cannot be obtained in time for the surgical preparation window.

Current U.S. Availability: What Prescribers Need to Know

Phenoxybenzamine is not on the FDA active shortage database as of early 2026. However, the practical experience of prescribers and patients is that this drug is nearly impossible to find at standard retail pharmacies. The underlying causes are structural:

Pheochromocytoma incidence is approximately 2-8 cases per million population annually in the U.S., translating to roughly 500-1,000 new diagnoses per year — insufficient to sustain broad retail pharmacy stocking

The cash price of generic phenoxybenzamine exceeds $6,700 per 30-day supply (60 capsules) at standard retail pharmacies, with no manufacturer patient assistance program

Treatment duration is typically short-term (1-4 weeks), so retail pharmacies have minimal incentive to maintain inventory

Manufacturing is concentrated among very few producers (ANI Pharmaceuticals for U.S. generic); internationally, Dibenzyline was listed as unavailable in Australia in 2025-2026 under TGA medicine shortage provisions

Clinical Impact: Why Delayed Access Is a Surgical Risk

Adequate preoperative alpha-blockade is standard of care for pheochromocytoma resection. Insufficient preoperative preparation is associated with:

Intraoperative hypertensive crises during tumor manipulation

Perioperative cardiovascular complications including arrhythmias, pulmonary edema, and myocardial ischemia

Increased intraoperative vasodilator requirements and fluid resuscitation needs

At least one case report has documented cardiac arrest during pheochromocytoma surgery attributable to inadequate outpatient dosage adjustment of phenoxybenzamine. The standard preoperative course of 7 to 14 days (with some centers using 2-4 weeks) leaves little margin for delays in accessing the drug.

Evidence-Based Alternatives When Phenoxybenzamine Is Unavailable

A substantial body of clinical literature supports the use of selective alpha-1 blockers as alternatives to phenoxybenzamine for pheochromocytoma preoperative preparation:

Doxazosin (Cardura): The most extensively studied alternative. The PRESCRIPT trial (first RCT in this indication) found no significant difference in primary clinical outcomes between doxazosin and phenoxybenzamine. Phenoxybenzamine showed slightly less intraoperative hemodynamic variability, but this did not translate to fewer cardiovascular complications. Doxazosin costs approximately 100-fold less than phenoxybenzamine and is available at any pharmacy. Starting dose: 1-2 mg/day; typical maintenance 2-8 mg/day; maximum 16 mg/day.

Prazosin (Minipress): Multiple retrospective studies and one prospective comparison show comparable perioperative hemodynamics versus phenoxybenzamine. Shorter half-life requires BID-TID dosing; typical range 2-20 mg/day in divided doses. Widely available and inexpensive.

Terazosin (Hytrin): Acceptable alternative with once-daily dosing advantage. Evidence base smaller than doxazosin but generally consistent results. Dose range 2-10 mg/day.

Calcium channel blockers (as adjuncts or monotherapy for select patients): Nicardipine (60-120 mg/day), amlodipine (5-10 mg/day), or nifedipine CR (30-60 mg/day) can be used as adjuncts to any alpha-blocker or as primary agents in patients with smaller tumors, mild-to-moderate hypertension, or who cannot tolerate alpha-blockers. Multiple studies show similar intraoperative hemodynamic stability to alpha-blockers in appropriately selected patients.

Metyrosine (Demser) as adjunct: Consider adding metyrosine 250-1000 mg/day to any alpha-blocker for large tumors, bilateral disease, or refractory hypertension. Reduces catecholamine synthesis. Monitor for sedation, depression, and extrapyramidal effects.

Key Clinical Reminders When Using Alpha-Blockers

Always initiate alpha-blockade before beta-blockade. Initiating a beta-blocker before adequate alpha-blockade can precipitate a hypertensive crisis due to unopposed alpha-mediated vasoconstriction.

Advise patients on high-sodium diet and fluid intake to counteract the vasodilation and volume expansion effect of alpha-blockade.

Monitor for orthostatic hypotension at every titration step, especially with phenoxybenzamine (target: standing SBP > 90 mmHg).

Avoid epinephrine in phenoxybenzamine-treated patients — the paradoxical vasodilatory response to epinephrine (due to beta stimulation with alpha blockade) can cause severe hypotension.

How medfinder Can Support Your Patients

When you send patients home with a phenoxybenzamine prescription, a referral to medfinder can prevent the access delays that put your surgical timeline at risk. medfinder calls pharmacies on behalf of your patient, identifies which locations can fill the prescription, and texts the results directly to the patient — reducing the chance they will come back to your office days later having been unable to fill it anywhere.

See also: How to Help Your Patients Find Phenoxybenzamine In Stock: A Provider's Guide.